Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

It's Good to be Eli Lilly in 2022 Says Citi Analyst

Published 08/25/2022, 03:18 PM
Updated 08/25/2022, 03:25 PM
© Reuters It's Good to Be Eli Lilly (LLY) in 2022 Says Citi Analyst

© Reuters It's Good to Be Eli Lilly (LLY) in 2022 Says Citi Analyst

By Sam Boughedda

Eli Lilly & Co.'s (NYSE:LLY) price target was raised to $370 from $285, with its Buy rating maintained at Citi on Thursday.

An analyst stated in his research note that "it's good to be Lilly in 2022."

"We have increased our peak risk-adjusted tirzepatide forecasts (diabetes/obesity/NASH) to >$25bn (previously $15bn, consensus c.$16bn). Our ongoing feedback from physicians/payers continues to fuel our optimism for broader access, reimbursement and adoption given the previously unforeseen glucose and weight lowering properties (US physician/payer survey, Mar-22)," said the analyst.

The analyst told investors they would use any potential weakness on the back of forthcoming data from Eisai's lecanemab and/or Roche's gantenerumab as an attractive opportunity to add to positions.

In addition, Citi "continue[s] to attribute a c.65% probability that LLY's TRAILBLAZER-ALZ 2 meets its primary endpoint in mid-2022."

Despite a dip earlier in the session, Eli Lilly shares are up 0.85% at the time of writing.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.